A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.
← catalyst calendarNCT05773586 · readout in 498 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
105estimated
Sites
2
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-13 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Anemia
Interventions
- Drug: APG-5918
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTreatment-Emergent Adverse Events (TEAEs)
measured up to 7 days in Part A and 84 days or till EOT in Part B
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed